Cemsidomide - C4 Therapeutics
Alternative Names: CFT 7455Latest Information Update: 23 Sep 2025
At a glance
- Originator C4 Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action IKZF1 protein degraders; IKZF3 protein degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Multiple myeloma; Non-Hodgkin's lymphoma
Most Recent Events
- 20 Sep 2025 Efficacy adverse events and pharmacodynamic data from a phase I/II trial in Multiple myeloma released by C4 Therapeutics
- 20 Sep 2025 C4 Therapeutics plans a phase Ib trial for Multiple myeloma (Combination therapy) in the second quarter of 2026
- 20 Sep 2025 C4 Therapeutics plans a phase II trial for peripheral T-cell lymphoma in the first quarter of 2026